Philips reported strong Q3 2026 results with an 8% increase in comparable order intake and 3% sales growth, driven by its Diagnosis & Treatment, Personal Health, and Connected Care segments. The adjusted EBITA margin rose by 70 basis points to 13.0%, supported by innovation, productivity gains, and higher sales. Philips also reached a key agreement with the US Department of Justice related to Respironics and reiterated its full-year 2026 outlook, expecting continued growth and margin improvement. The company highlighted ongoing investments in AI and advanced imaging technologies and remains focused on quality and customer demand.
Philips shares trade at USD 27.14 on Pluang as of Nov 03, 2026 13:11 WIB, up 0.80% for the day. The stock's market cap stands at $26.49 billion, with a dividend yield of 3.76%. Investors hold shares for an average of 86 days, reflecting steady interest in the health sector company.
Philips has introduced the HyperVue Integrated System in the U.S., a fixed, single-room setup combining DeepOCT+NIRS imaging with X1-FFR physiology assessment for coronary interventions. This system is designed to streamline cath lab workflows by kee...
Philips has introduced UniGuide 3D Live Guidance, a new CE-marked solution that integrates CT-derived planning insights directly into live procedures using its Azurion image-guided therapy platform. This technology allows physicians to access detaile...
